Larry G. Edwards - 30 Jun 2021 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO

Role: Chief Executive Officer
Signature: /s/ Larry Edwards
Issuer symbol: N/A
Transactions as of: 30 Jun 2021
Net transactions value: +$1,146
Form type: 4
Filing time: 02 Jul 2021, 20:46:06 UTC
Previous filing: 17 Jun 2021
Next filing: 19 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LJPC	Common Stock	Award	$1,146	+315	+20%	$3.64	1,888	30 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LJPC	Employee Stock Option (Right to Buy)	Award	$0	+315		$0.000000	315	30 Jun 2021	Common Stock	315	$4.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired on 6/30/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.